胰岛素
内质网
葡萄糖稳态
糖尿病
胞吐
生物
遗传增强
分泌物
翻译(生物学)
平衡
基因表达
内分泌学
细胞生物学
免疫系统
细胞
内科学
医学
生物信息学
基因沉默
合成生物学
基因
基因表达调控
细胞疗法
1型糖尿病
蛋白质生物合成
神经科学
下调和上调
阳离子脂质体
作者
Lifang Xie,Wanling Lu,Jiayang Yu,Yanhan Zhang,Hong Gao,Chunguang Xie,Yun Tian,Ming Liu,Gang Wang
标识
DOI:10.1093/ejendo/lvaf231
摘要
Achieving physiological glucose homeostasis in insulin-deficient diabetes remains challenging because exogenous insulin and devices cannot recapitulate the real-time, glucose-responsive secretion of pancreatic β-cells. This review aims to delineate the conceptual framework and recent advances in regulating insulin expression and release through gene- and cell-based therapies, emphasizing strategies that approximate native β-cell dynamics. We summarize progress in glucose-responsive insulin gene expression in hepatocytes, skeletal muscle, intestinal K/L cells, and residual pancreatic β-cells via synthetic promoters and circuit engineering that couple metabolic cues to transcription. We then evaluate rapid-release platforms that uncouple biosynthesis from secretion. These include endoplasmic reticulum retention-release switches and engineered vesicle-based exocytosis modules that, when actuated by metabolic, optical, electrical, or small-molecule cues, reproduce first-phase-like insulin kinetics. Finally, we highlight synthetic-biology frameworks integrating chemical, metabolic, optical, electrical, and magnetic inputs to program autonomous and reversible insulin output. We conclude with a focused translational agenda: strengthen biosafety and genetic stability; induce immune tolerance and alleviate reticulum retention stress; ensure durable, tissue-specific expression; standardize non-viral/viral delivery systems for scalable manufacturing; and integrate molecular circuits with continuous glucose monitors to achieve closed-loop, hypoglycemia-safe control. These priorities will accelerate clinical translation toward intelligent, patient-tailored insulin therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI